TABLE 3.
Uni- and multivariate analysis of RFS and OS for CLM.
| Parameters | mRFS (95%CI) | p | HRCox1 (95%CI) | pCox1 | HRCox2 (95%CI) | pCox2 |
|---|---|---|---|---|---|---|
| Age | ||||||
| <62 | 6.6 (4.4–8.9) | 7 × 10−4 | - | - | ||
| ≥62 | 14.6 (10.2–16.8) | |||||
| Resection margin | ||||||
| R0 | 13.8 (8.3–17.8) | 0.001 | 1 (ref) | 0.048 | 1 (ref) | 0.182 |
| R1 | 6.6 (5.2–10) | 1.42 (1.003–2.1) | 1.3 (0.89–1.9) | |||
| Synchronous | ||||||
| yes | 8.2 (2–8.2) | 0.012 | - | - | ||
| no | 12.9 (7–14.6) | |||||
| Postoperative chemotherapy ± targeted therapy | ||||||
| none | 5.5 (2–5.8) | 3 × 10−4 | - | 1 (ref) | 0.012 | |
| yes | 13.4 (9.9–16.3) | 0.61 (0.42–0.9) | ||||
| Pre- or postoperative chemotherapy ± targeted therapy | ||||||
| none | 2.5 (2–2.5) | 0.006 | - | - | ||
| yes | 10.8 (8.2–13.9) | |||||
| WBC | ||||||
| <6.8 | 14.6 (10.8–19.3) | 0.011 | - | - | ||
| ≥6.8 | 8.3 (5.5–10.2) | |||||
| Neutrophil | ||||||
| <4 | 19.3 (10.8–24.9) | 0.002 | - | - | ||
| ≥4 | 8.3 (5.8–10.5) | |||||
| NLR | ||||||
| <2 | 14.6 (6.8–24.2) | 0.004 | 1 (ref) | 0.03 | - | |
| ≥2 | 9.9 (6–12.7) | 1.44 (1.04–1.99) | ||||
| SII | ||||||
| <535 | 14.4 (10.5–19.3) | 0.005 | - | 1 (ref) | 0.229 | |
| ≥535 | 8.2 (5–9.9) | 1.24 (0.87–1.78) | ||||
| GOT | ||||||
| <24 | 12.9 (8.3–17.8) | 0.043 | 1 (ref) | 0.043 | 1 (ref) | 0.013 |
| ≥24 | 6.8 (5.5–10.5) | 1.43 (1.01–2.02) | 1.6 (1.1–2.33) | |||
| GPT | ||||||
| <31 | 12.7 (7–14.4) | 0.03 | - | - | ||
| ≥31 | 5 (3.2–8.9) | |||||
| mOS (95% CI) | ||||||
| WBC | ||||||
| <7.1 | NR (40.5–46.6) | 0.004 | - | - | ||
| ≥7.1 | 30.1 (23.2–37.5) | |||||
| Neutrophil | ||||||
| <4.8 | NR (34.4–46.6) | 0.004 | - | 1 (ref) | 0.114 | |
| ≥4.8 | 30.1 (23.2–37.5) | 1.45 (0.91–2.31) | ||||
| Lymphocyte | ||||||
| <2 | 68.3 (42.1–68.3) | 0.005 | - | 1 (ref) | 0.053 | |
| ≥2 | 31.3 (24.2–34.4) | 1.63 (0.99–2.67) | ||||
| Platelet | ||||||
| <184 | 24.2 (17.9–33.1) | 0.045 | 1 (ref) | 0.853 | - | |
| ≥184 | 42.1 (31.3–68.3) | 1.06 (0.59–1.9) | ||||
| GOT | ||||||
| <24 | NR (39.7–42.1) | 0.021 | 1 (ref) | 0.073 | 1 (ref) | 0.233 |
| ≥24 | 31.3 (24.6–40.8) | 1.64 (0.96–2.81) | 1.4 (0.81–2.41) | |||
| GPT | ||||||
| <17 | NR (−33.1) | 0.011 | - | - | ||
| ≥17 | 34.4 (25–40.8) | |||||
| Extent of progression | ||||||
| single | 37.5 (31.1–46.6) | 0.016 | 1 (ref) | 0.043 | 1 (ref) | 0.011 |
| multiple | 20.3 (16.3–24.2) | 1.71 (1.02–2.88) | 1.98 (1.17–3.34) | |||
CI, confidence interval; Cox(1 or 2), multivariate Cox regression analysis (model 1 or 2); GOT, aspartate aminotransferase; GPT, alanine aminotransferase; HR, hazard ratio; mOS, median overall survival; mRFS, median relapse-free survival; NLR, neutrophil-to lymphocyte ratio; NR, not reached; ns, not significant; ref, reference; SII, systemic immune-inflammation index; WBC, white blood cells.